MBX
MBX Biosciences·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MBX
Mbx Biosciences, Inc.
A clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapeutics for the treatment of endocrine and metabolic diseases
11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032
Develops precision peptide therapies for endocrine and metabolic disorders.
MBX Biosciences, Inc., was incorporated as an Indiana limited liability company in August 2018 and transformed into a Delaware corporation in April 2019. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for endocrine and metabolic diseases. Its R&D pipeline includes drug candidates for hypoparathyroidism, obesity and postbariatric hypoglycemia designed using its proprietary Precision Endocrine Peptide Platform.
Company Financials
EPS
MBX has released its 2026 Q2 earnings. EPS was reported at -0.78, versus the expected -0.63, missing expectations. The chart below visualizes how MBX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
